Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group

对健康人群中CoronaVac 28天接种方案诱导的免疫反应进行评估

阅读:5
作者:Alejandro Escobar ,Felipe E Reyes-López ,Mónica L Acevedo ,Luis Alonso-Palomares ,Fernando Valiente-Echeverría ,Ricardo Soto-Rifo ,Hugo Portillo ,Jimena Gatica ,Ivan Flores ,Estefanía Nova-Lamperti ,Carlos Barrera-Avalos ,María Rosa Bono ,Leonardo Vargas ,Valeska Simon ,Elias Leiva-Salcedo ,Cecilia Vial ,Juan Hormazabal ,Lina Jimena Cortes ,Daniel Valdés ,Ana M Sandino ,Mónica Imarai ,Claudio Acuña-Castillo

Abstract

CoronaVac vaccine from Sinovac Life Science is currently being used in several countries. In Chile, the effectiveness of preventing hospitalization is higher than 80% with a vaccination schedule. However, to date, there are no data about immune response induction or specific memory. For this reason, we recruited 15 volunteers without previous suspected/diagnosed COVID-19 and with negative PCR over time to evaluate the immune response to CoronaVac 28 and 90 days after the second immunization (dpi). The CoronaVac administration induces total and neutralizing anti-spike antibodies in all vaccinated volunteers at 28 and 90 dpi. Furthermore, using ELISpot analysis to assay cellular immune responses against SARS-CoV-2 spike protein, we found an increase in IFN-gamma- and Granzyme B-producing cells in vaccinated volunteers at 28 and 90 dpi. Together, our results indicate that CoronaVac induces a robust humoral immune response and cellular immune memory of at least 90 dpi.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。